|
AU2003301906A1
|
|
Production of ubiquitin fusion proteins
|
|
WO2004044007A1
|
|
Production of ubiquitin fusion proteins
|
|
AU2003259072A8
|
|
Compositions and methods for neural differentiation of embryonic stem cells
|
|
AU2003903152A0
|
|
Modifying mammalian genomes
|
|
AU2003902163A0
|
|
Methods for Treating Injuries or Illnesses with an Inflammatory Antagonist
|
|
AU2003901107A0
|
|
Methods for the production of protein or peptides
|
|
AU2003900765A0
|
|
Method fro treating cancer and cancer realted diseases
|
|
AU2002953309A0
|
|
Methods for Identifying and Separating Populations of Pluripotent Cells
|
|
AU2002952591A0
|
|
Methods for the production of protein or peptides
|
|
AU2002952398A0
|
|
Receptor expressed in pluripotent cells
|
|
AU2002951169A0
|
|
Neural facilitation factor
|
|
AU2002950220A0
|
|
Prolonged release composition
|
|
AUPS313902A0
|
|
Modifying mammalian genomes
|
|
AUPS225402A0
|
|
Modified cell production
|
|
AU1884802A
|
|
Cellular production control
|
|
AUPR894001A0
|
|
Treatment of Oocytes
|
|
WO0238741A1
|
|
Cell reprogramming
|
|
AUPR663501A0
|
|
A method of administering a gm-csf antagonist
|
|
AUPR617701A0
|
|
Neuronal cell production
|
|
US6749833B2
|
|
Design and planning system for improving the survival rate of injected structures
|
